




RealRate

HEALTH SERVICES 2022

Viridian Therapeutics Inc.\DE Rank 25 of 94





RealRate

HEALTH SERVICES 2022

Viridian Therapeutics Inc.\DE Rank 25 of 94



The relative strengths and weaknesses of Viridian Therapeutics Inc.\DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc.\DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 290% points. The greatest weakness of Viridian Therapeutics Inc.\DE is the variable Net Income, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 192%, being 101% points above the market average of 92%.

Input Variable	Value in 1000 USD
Assets, Current	200,163
Assets, Non-Current	3,171
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	25,805
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	13,636
Long Term Liabilities	1,208
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-149
Other Expenses	56,889
Other Liabilities	1,149
Other Net Income	318
Other Revenues	2,963
Property Plant and Equipment	375
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	203,709
Liabilities	15,993
Expenses	82,694
Revenues	2,963
Stockholders Equity	187,716
Net Income	-79,413
Comprehensive Net Income	-79,562
Economic Capital Ratio	192%